We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

252 hedge funds and large institutions have $4.58B invested in Iovance Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 91 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $52.7M | Put options by funds: $26.5M

18% more capital invested

Capital invested by funds: $3.88B → $4.58B (+$704M)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

0.67% less ownership

Funds ownership: 96.25% → 95.58% (-0.67%)

9% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 91

10% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 51

2% less funds holding

Funds holding: 257 → 252 (-5)

Holders
252
Holders Change
-5
Holders Change %
-1.95%
% of All Funds
5.08%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
46
Increased
83
Reduced
91
Closed
51
Calls
$52.7M
Puts
$26.5M
Net Calls
+$26.2M
Net Calls Change
-$19.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$112M
2
Franklin Resources
Franklin Resources
California
+$41.6M
3
NAMA
Nikko Asset Management Americas
New York
+$23.5M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$23.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.4M

Top Sellers

1
PA
Perceptive Advisors
New York
-$52.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$30M
3
ACA
Avoro Capital Advisors
New York
-$25.3M
4
EAM
Eagle Asset Management
Florida
-$19.8M
5
Goldman Sachs
Goldman Sachs
New York
-$18.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
76
RhumbLine Advisers
Massachusetts
$4.82M -$251K -8,171 -5%
IBT
77
International Biotechnology Trust
United Kingdom
$4.77M +$4.45M +145,000 New
Allianz Asset Management
78
Allianz Asset Management
Germany
$4.68M -$2.07M -67,463 -32%
American Century Companies
79
American Century Companies
Missouri
$4.19M -$957K -31,232 -20%
PM
80
Prosight Management
Texas
$3.97M -$2.89M -94,394 -44%
Wells Fargo
81
Wells Fargo
California
$3.85M -$1.43M -46,756 -29%
Legal & General Group
82
Legal & General Group
United Kingdom
$3.68M -$9.66K -315 -0.3%
Alyeska Investment Group
83
Alyeska Investment Group
Illinois
$3.66M -$6.13M -200,000 -64%
PPA
84
Parametric Portfolio Associates
Washington
$3.65M -$1.17M -38,051 -26%
Neuberger Berman Group
85
Neuberger Berman Group
New York
$3.62M +$460K +15,000 +16%
Morgan Stanley
86
Morgan Stanley
New York
$3.56M -$1.4M -45,697 -30%
6CM
87
683 Capital Management
New York
$3.29M – – –
Dimensional Fund Advisors
88
Dimensional Fund Advisors
Texas
$3.22M +$947K +30,894 +46%
PF
89
Phoenix Financial
Israel
$3.1M +$3.07M +100,000 New
GC
90
Guggenheim Capital
Illinois
$2.72M -$919K -29,961 -27%
FMBTD
91
First Midwest Bank Trust Division
Illinois
$2.63M +$691K +22,551 +39%
CIA
92
Capital Impact Advisors
Massachusetts
$2.63M +$2.45M +80,000 New
ACH
93
ArrowMark Colorado Holdings
Colorado
$2.56M – – –
State of New Jersey Common Pension Fund D
94
State of New Jersey Common Pension Fund D
New Jersey
$2.55M +$270K +8,792 +13%
SFI
95
Susquehanna Fundamental Investments
Pennsylvania
$2.53M – – –
UBS Group
96
UBS Group
Switzerland
$2.37M +$818K +26,685 +59%
MAP
97
Moody Aldrich Partners
Massachusetts
$2.16M +$29.2K +952 +1%
E
98
Ergoteles
New York
$2.09M +$1.94M +63,352 New
EAM
99
Eagle Asset Management
Florida
$2.06M -$19.8M -644,786 -91%
Rafferty Asset Management
100
Rafferty Asset Management
New York
$2.06M +$927K +30,227 +93%
2 3
4
5 6

IOVA Hedge Fund Activity: Q3 2020 in Review

252 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2020, worth a combined $4.58B — up 18% from $3.88B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of IOVA and 46 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 83 added.

The largest buyer was ARK Investment Management, adding an estimated $112M. The largest seller was Perceptive Advisors, cutting an estimated $52.8M.

  • 252 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2020, down from 257 in Q2 2020.
  • Funds reported $4.58B of Iovance Biotherapeutics stock for Q3 2020, up 18% quarter-over-quarter.
  • 46 funds opened new Iovance Biotherapeutics positions in Q3 2020 and 51 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q3 2020 was ARK Investment Management, an estimated $112M added.
  • The largest Iovance Biotherapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $52.8M sold.

Based on aggregated 13F filings for Q3 2020.